Sepsis kills. It strikes fast, hides in plain sight, and mimics other conditions — making it one of the most dangerous and time-sensitive medical emergencies. Every hour delay in treatment increases mortality by up to 8%. Yet diagnosis remains a challenge: symptoms like fever, confusion, and rapid breathing are non-specific, and traditional lab tests take hours or days to return.

That’s where AQEMIA comes in — not just another diagnostic tool, but a revolutionary blood test powered by AI and molecular biology designed to help doctors detect sepsis earlier, with greater accuracy, and from a single drop of blood.

Unlike blood cultures that take 2–5 days, AQEMIA analyzes immune response patterns at the gene expression level, identifying the body’s real-time reaction to infection — often before bacteria are even detectable in the bloodstream.

It’s not about waiting for confirmation — it’s about acting with confidence from the first hour.

Tool Overview: What is AQEMIA?

AQEMIA is a rapid, AI-enhanced diagnostic platform designed for emergency departments, ICUs, and critical care units that want to reduce sepsis mortality, avoid unnecessary antibiotics, and improve patient outcomes.

The platform works by:

• Analyzing a small blood sample (fingerstick or venous) using RT-PCR and machine learning
• Measuring immune system gene expression patterns associated with bacterial infection
• Delivering a “Sepsis Likelihood Score” within 60 minutes — distinguishing sepsis from viral illness or inflammation
• Integrating with hospital EHRs to support clinical decision-making

Used in hospitals across Europe and clinical trials in North America, AQEMIA replaces clinical guesswork and delayed cultures with a data-driven, early warning system — so clinicians can start life-saving treatment faster, or confidently hold antibiotics when not needed.

It doesn’t just test blood — it interprets the body’s alarm system.

Key Features of AQEMIA

1. Rapid Sepsis Detection (<60 Minutes)
   Get actionable results while the patient is still in the ER — not 48 hours later.
2. Host Response-Based Testing
   Measures the body’s immune reaction — not just pathogens — for earlier detection.
3. AI-Powered Risk Scoring
   Delivers a clear, easy-to-interpret Sepsis Likelihood Score (Low, Medium, High).
4. Differentiates Bacterial vs. Viral Infections
   Helps avoid unnecessary antibiotic use — supporting antimicrobial stewardship.
5. Works Before Cultures Turn Positive
   Detects sepsis even when blood cultures are still negative.
6. Minimal Sample Requirement
   Can use small volumes — ideal for pediatric or critically ill patients.
7. CE-Marked & Clinically Validated
   Backed by peer-reviewed studies in journals like Critical Care and Intensive Care Medicine.
8. EHR Integration Ready
   Push results directly into patient charts for seamless workflow adoption.
9. Supports Sepsis Bundles & Quality Metrics
   Helps hospitals meet early intervention benchmarks (e.g., SEP-1).
10. Designed for Point-of-Care Use
    Compact analyzer fits in emergency labs or ICU satellite stations.

Benefits of Using AQEMIA

• Reduce Time to Diagnosis by Up to 48 Hours
  Start appropriate treatment while others are still waiting for cultures.
• Perfect for ER Physicians & Intensivists
  Make faster, more confident decisions in high-stakes cases.
• Great for Hospital Quality & Safety Teams

  Improve sepsis bundle compliance and reduce mortality rates.

• Ideal for Pediatric & Geriatric Units
  Detect sepsis in populations with atypical presentations.
• Reduces Antibiotic Overuse
  Avoid unnecessary prescriptions by ruling out bacterial infection.
• Improves Patient Outcomes
  Early detection = faster treatment = lower mortality and shorter ICU stays.
• Supports Antimicrobial Stewardship Programs
  Meet hospital and regulatory goals for responsible antibiotic use.
• No Heavy Setup Required
  Deploy with minimal training — works with existing lab infrastructure.
• Actionable Output Without the Noise
  Get a clear clinical answer — not just raw data or probabilities.
• Future-Proofs Your Critical Care Strategy
  As precision diagnostics grow, AQEMIA positions you at the forefront.

Who Can Benefit from AQEMIA?

• Emergency Physicians: Triage sepsis faster and more accurately.
• Intensivists & ICU Teams: Monitor at-risk patients with precision.
• Hospital Lab Directors: Offer rapid molecular diagnostics without outsourcing.
• Infectious Disease Specialists: Guide therapy with confidence.
• Quality & Patient Safety Officers: Reduce sepsis-related mortality and readmissions.
• Pediatric & Geriatric Care Units: Catch sepsis in vulnerable populations early.

Real-World Impact: How Hospitals Use AQEMIA

• A university hospital in France reduced sepsis mortality by 27% after integrating AQEMIA into its ER protocol.
• An ICU in Germany cut unnecessary antibiotic use by 33% — thanks to viral vs. bacterial differentiation.
• A pediatric emergency unit diagnosed sepsis in a 4-year-old 12 hours before cultures turned positive — enabling life-saving intervention.
• A rural hospital gained access to advanced sepsis diagnostics — without sending samples to distant labs.

Final Thoughts

AQEMIA isn’t just another lab test — it’s a game-changer in critical care diagnostics, helping clinicians move from reactive guessing to proactive precision. By combining molecular science, AI interpretation, and speed, it becomes more than just a device — it becomes a silent guardian in the fight against one of medicine’s deadliest threats.

If you’re tired of waiting for cultures, missing early signs, or starting antibiotics “just in case,” AQEMIA could be exactly what you need to bring clarity, speed, and confidence back to sepsis care.